PRTG

PRTG (Protogenin) is a transmembrane immunoglobulin-superfamily receptor that marks a transitional developmental stage and suppresses premature neuronal differentiation, defining the window between pluripotent epiblasts and committed neural progenitors (PMID:20335479). It functions as a ligand-activated receptor: ERdj3, a stress-inducible ER DnaJ homolog, binds PRTG and acts as a ligand that suppresses neurogenesis (PMID:20335479), and PRTG signals through Radil to convert α5β1-integrins to high-affinity conformations, forming an ERdj3/PRTG/Radil/α5β1-integrin axis that promotes cephalic neural crest cell survival and migration (PMID:23744351). In addition to signaling, PRTG mediates homophilic cell adhesion to control the timing of paraxial mesoderm ingression and somite organization (PMID:21129372), and it is processed by sequential proteolysis culminating in γ-secretase cleavage that releases a nuclear-translocating intracellular domain (PRTG-ICD) (PMID:22150322). PRTG also integrates into TGFβ-family signaling by physically interacting with GDF11 to sustain phospho-Smad2 activity, driving posterior HOX gene expression and vertebral patterning (PMID:39702818). Its expression is tightly tuned by microRNAs across contexts—let-7/miR-125/miR-9 in retinal progenitors (PMID:23754433) and miR-9 in chondroblasts, where PRTG promotes caspase-3–dependent apoptosis (PMID:24007463). In disease settings, PRTG is transcriptionally induced by ZEB1 downstream of H. pylori to activate cGMP/PKG signaling and drive gastric cancer progression (PMID:33542225).

1. 2010 High

   Established PRTG's core developmental role by showing it defines and maintains an undifferentiated transition stage, answering whether this early embryonic receptor restrains neural commitment.

   Evidence RNAi knockdown, dominant-negative overexpression, and in vitro/in ovo differentiation assays in P19 cells and chick embryos

   PMID:20335479

   Open questions at the time

   • Did not identify the downstream effectors linking PRTG to differentiation control
   • Mechanism of how PRTG senses the timing signal unresolved
2. 2010 High

   Identified ERdj3 as a PRTG ligand, answering what extracellular cue engages the receptor to suppress neurogenesis.

   Evidence Yeast two-hybrid screen, in situ binding assay, neutralizing antibody and ectodomain competition with purified ERdj3 in differentiation assays

   PMID:20335479

   Open questions at the time

   • Did not define the intracellular signaling cascade triggered by ERdj3 binding
   • Physiological source/availability of secreted ERdj3 in vivo not established
3. 2010 Medium

   Placed PRTG upstream of BMP4 in tooth morphogenesis, extending its role beyond the neural lineage.

   Evidence Antisense oligonucleotide inhibition in cultured mouse mandible explants with Bmp4 expression readout

   PMID:21108791

   Open questions at the time

   • Direct versus indirect regulation of Bmp4 not distinguished
   • No receptor signaling mechanism defined in this context
4. 2010 High

   Demonstrated PRTG mediates homophilic adhesion to control mesoderm ingression, distinguishing an adhesion function from its signaling role.

   Evidence L-cell aggregation assay plus in ovo gain- and loss-of-function in chick paraxial mesoderm

   PMID:21129372

   Open questions at the time

   • Structural basis of homophilic binding not defined
   • Relationship between adhesion and ligand-dependent signaling unresolved
5. 2011 Medium

   Showed PRTG undergoes γ-secretase–dependent cleavage releasing a nuclear ICD, raising the possibility of direct receptor-to-nucleus signaling.

   Evidence Biochemical cleavage analysis, γ-secretase inhibitor experiments, and subcellular localization in cultured cells and chick embryos

   PMID:22150322

   Open questions at the time

   • Nuclear targets or transcriptional activity of PRTG-ICD unknown
   • Single lab without full mutagenesis controls
6. 2013 High

   Resolved the intracellular signaling axis by placing Radil downstream of PRTG to activate α5β1-integrins, explaining how ERdj3/PRTG promotes neural crest survival and migration.

   Evidence Prtg knockout mice with lineage tracing, yeast two-hybrid, integrin conformational activation assay, RNAi epistasis, and transwell migration

   PMID:23744351

   Open questions at the time

   • Biochemical link between PRTG cytoplasmic domain and Radil not mapped
   • How integrin activation feeds back to differentiation control unclear
7. 2013 Medium

   Revealed a context-specific pro-apoptotic role for PRTG in chondroblasts under miR-9 control, contrasting its pro-survival function in neural crest.

   Evidence miR-9 target validation, PRTG overexpression with caspase-3 activity assay, and siRNA rescue in chondroblasts

   PMID:24007463

   Open questions at the time

   • Mechanism linking PRTG to caspase-3 activation unknown
   • Reconciliation with PRTG pro-survival signaling not addressed
8. 2013 Medium

   Showed miRNA-driven downregulation of PRTG is required for temporal progression of retinal neurogenesis, confirming PRTG as a brake on progenitor maturation.

   Evidence Microarray target identification in Dicer-CKO retinas and overexpression rescue in retinal progenitors

   PMID:23754433

   Open questions at the time

   • Direct miRNA-PRTG targeting not biochemically confirmed in this study
   • Downstream effectors maintaining the progenitor state unidentified
9. 2021 Medium

   Connected PRTG to gastric cancer pathogenesis by showing H. pylori–driven ZEB1 induces PRTG to activate cGMP/PKG signaling.

   Evidence ZEB1 promoter recruitment, PRTG loss-of-function in cells and tumor-bearing mice, and PKG inhibitor (KT5823) treatment

   PMID:33542225

   Open questions at the time

   • How PRTG mechanistically activates cGMP/PKG signaling not defined
   • Whether ERdj3/Radil/integrin axis operates in this cancer context untested
10. 2024 High

    Integrated PRTG into TGFβ-family signaling by showing it binds GDF11 to sustain pSmad2 and drive posterior HOX activation and vertebral patterning.

    Evidence Prtg knockout mice, transcriptomics, pSmad2 immunodetection, co-IP with GDF11, and hiPSC-PSM differentiation with GDF11 rescue

    PMID:39702818

    Open questions at the time

    • Whether PRTG acts as a co-receptor for GDF11 or stabilizes ligand availability not resolved
    • Relationship between GDF11/Smad2 role and the ERdj3/Radil axis unknown
11. 2023 Low

    Proposed WFIKKN2 as a ligand acting through DCC-family receptors including PRTG in axon guidance, expanding the receptor's ligand repertoire.

    Evidence Ligand-receptor binding identification and axon guidance assays in mouse sensory and motor axons (preprint)

    PMID:37398498

    Open questions at the time

    • PRTG-specific WFIKKN2 functional interaction not independently validated
    • Preprint, not peer reviewed
    • Downstream signaling from WFIKKN2-PRTG unmapped
12. 2026 Medium

    Identified a miR-4458/PRTG axis in vascular smooth muscle cell dedifferentiation, extending PRTG regulation to cardiovascular phenotypic transformation.

    Evidence Dual-luciferase reporter assay, miR-4458 and PRTG gain/loss-of-function, viability and migration assays in ox-LDL-treated VSMCs

    PMID:41631733

    Open questions at the time

    • Mechanistic link between PRTG and retinoic acid signaling not defined
    • Single lab, single study

• How PRTG's multiple, context-dependent activities—adhesion, ERdj3/Radil/integrin signaling, GDF11/Smad2 modulation, γ-secretase ICD release, and pro-apoptotic versus pro-survival outputs—are coordinated by a single receptor remains unresolved.
• No structural model of ligand engagement or domain function
• Nuclear targets of PRTG-ICD unidentified
• Mechanism switching PRTG between pro-survival and pro-apoptotic outputs unknown